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Objective: The purpose of this study was to assess prospectively the incidence, health care resource utilization, and
economic burden associated with perioperative myocardial ischemic injury (PMII) in high-risk patients undergoing
noncardiac vascular surgery.
Methods: Two hundred thirty-six patients consented to participate in a pharmacoeconomic substudy as part of a
randomized, multicenter clinical trial. Patients were assessed formyocardial ischemic injury by using clinical, biochemical,
and electrocardiographic criteria. PMII was defined as fatal or nonfatal myocardial infarction, new or worsened
congestive heart failure, or new arrhythmias. Resource utilization parameters were compared for patients with and
without PMII. Patients underwent the following index procedures: open abdominal aortic aneurysm repair (n  44),
bypass for aortoiliac disease (n  29), bypass for femoropopliteal disease (n  62), bypass for femorotibial disease (n 
71), extra-anatomic bypass (n  23), and miscellaneous (n  7). Patients undergoing carotid endarterectomy or only
endovascular interventions were excluded. The incremental cost of PMII was estimated by applying the average costs
(adjusted to 2004US dollars) of the hospital ward ($700.00/d) or intensive care unit ($2500.00/d) to the length of stay
differences for patients with and without PMII.
Results: The overall mortality was 3.4% (8/236), and 7 of 8 deaths were related to PMII. PMII occurred in 42 (17.8%)
of 236 patients: 22 myocardial infarctions, 11 congestive heart failures, and 12 new arrhythmias (3 patients had 2 PMII
events). There was no evidence of differences in the incidence of PMII among the various index procedures. PMII was
associated with a dramatic increase in resource utilization. The mean length of stay was 16.8 and 10.0 days for patients
with and without PMII, respectively (P < .001). Intensive care unit care was required by 35 (83.3%) of 42 patients with
and 121 (62.4%) of 194 patients without PMII (P < .009). The mean intensive care unit length of stay was 6.6 and 3.7
days for patients with and without PMII, respectively (P< .009). Ten (23.8%) of 42 patients with and 20 (10.3%) of 194
patients without PMII returned to the emergency department for care after discharge (P < .02).
Conclusions: In modern vascular surgery practice, PMII remains common despite the availability of -blockers and other
preventative strategies. PMII is associated with dramatic increases in resource utilization and cost. The increase in
resource utilization associated with PMII resulted in an estimated incremental cost per patient of $9980.00. If 250,000
high-risk open vascular operations are performed annually in the United States, the economic burden of PMII in these
procedures alone approximates $444 million. Strategies to decrease PMII incidence and severity should be evaluated in
large-scale prospective trials. ( J Vasc Surg 2006;43:533-8.)In the United States, nearly 25 million patients un-
dergo noncardiac surgical procedures each year. More than
8 million of these patients have coronary artery disease or
risk factors for coronary artery disease, and approximately 1
million patients experience perioperative cardiac morbidity
or cardiac-related mortality.1-4 In the highest-risk group
are more than 500,000 patients undergoing noncardiac
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doi:10.1016/j.jvs.2005.11.013vascular surgery. The prevalence of coronary disease in
these patients and the hemodynamic stress often associated
with vascular surgery accounts for their observed high risk
of perioperative myocardial ischemic events.5-7
Perioperative myocardial ischemic injury (PMII) is a
marker for coronary artery disease–associated morbidity and
mortality.3 PMII can aggravate pre-existing cardiac condi-
tions or result in myocardial infarction (MI), unstable angina,
ventricular arrhythmia, congestive heart failure (CHF), or
sudden cardiac death during the period between the surgical
procedure and hospital discharge. Furthermore, it seems in-
tuitively obvious that PMII should increase the resource uti-
lization and cost associated with vascular surgery. Estimates
from the 1980s suggested that the in-hospital economic bur-
den of PMII for all noncardiac operations was more than $12
billion annually.4 Because of the aging of our population and
the ever-rising costs of health care, the economic burden
associated with PMII is of great interest to private and gov-
ernment health care insurance providers.
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effect, little is known about incremental PMII associated
resource utilization and cost. The spectrum of PMII runs
from clinically inapparent troponin leaks through major
transmural infarction or sudden cardiac death. Because
catastrophic perioperative events are unusual, it is tempting
for individual practitioners, who may see only one such
event per year, to ignore or downplay the significance of
PMII in their practice. The occasional subendocardial in-
farct, CHF episode, or rhythm disturbance may escape the
careful scrutiny of vascular surgeons, anesthesiologists, and
their quality-assurance departments. The primary objective
of this economic study was to measure prospectively the
incidence, resource utilization, and associated economic
burden of PMII in patients undergoing high-risk noncar-
diac vascular surgery in the United States.
METHODS
The study from which the patients for this pharmacoeco-
nomic (PE) substudy were recruited was a phase II inter-
national randomized double-blind multicenter placebo-
controlled trial that examined the effects of Zoniporide
compared with placebo.8 Zoniporide is a sodium hydrogen
ion exchange inhibitor that in animal models has been
shown to decrease myocardial injury related to ischemia-
reperfusion events when compared with placebo. In phase I
trials, the agent was proven safe for administration to
humans.
The inclusion criteria defined a noncardiac vascular
surgery population at high risk of PMII events.8 Eligibility
criteria included the following:
1. Age 18 years or older.
2. Open major vascular surgery (aortic or aortoiliofemoral
reconstruction for aneurysm or occlusive disease, extra-
anatomic bypass for aortoiliac disease, femoral recon-
struction, and femoropopliteal or tibial bypass).
3. Either (1) a history of three or more of the following:
age 70 years or older, documented stroke, prior MI,
medically managed coronary artery disease with active
angina pectoris (Canadian classII), diabetes mellitus,
CHF (New YorkHeart Association classII), or symp-
tomatic cardiac arrhythmia or (2) a history of one of
these risk factors and radionuclide/echocardiographic
and electrocardiographic evidence of reversible isch-
emia in response to exercise or pharmacologic stress.
The cardiac stress study must have been performed
within the previous year, and complete revascularization
must not have occurred before surgery. Subjects undergo-
ing emergency vascular procedures with risk factors, as
described previously, were also eligible if study procedures
could be followed and not delay the operation. Patients
undergoing carotid endarterectomy or endovascular surgi-
cal procedures were excluded.8
At each participating institution, the study protocol
and consent form were approved by the institutional review
board. Participation in the trial was contingent upon the
patient’s meeting eligibility criteria and consenting to par-ticipate. An additional approved consent form was required
for participation in this PE substudy. The 236 patients
participating represent all US subjects in the main clinical
trial who also consented to participate in this substudy.
The primary goal of the study was to compare the
zoniporide- and placebo-treated groups with respect to the
occurrence of cardiac end points (fatal or nonfatal MI, new
or progressive CHF, or serious cardiac arrhythmia) within
30 days of operation, as defined by an independent end
point classification committee that used routine surveil-
lance by cardiac biomarkers, electrocardiograms, and symp-
toms.
As part of the clinical trial, this PE substudy was con-
ducted in parallel to assess resource utilization through
postoperative day 30. All PE data were collected on clinical
trial case report forms that included overall hospital length
of stay, intensive care unit (ICU) length of stay, proce-
dures, rehospitalizations, emergency department visits,
physician visits, and other resource utilization parameters.
The clinical results within the primary zoniporide study
found no differences in the rates of cardiac events between
the treatment and placebo groups; thus, data were pooled
to perform resource utilization analysis to allow compari-
son between patients with and without PMII. To simplify
the analysis of resource utilization and cost, only patients
hospitalized in the US study sites were included in this
Table I. Distribution of index procedures
Procedure n
Open abdominal aortic aneurysm repair 44
Bypass for aortoiliac disease 29
Bypass for femoropopliteal disease 62
Bypass for femorotibial disease 71
Extra-anatomic bypass 23
Miscellaneous (eg, femoral endarterectomy) 7
Table II. Demographic characteristics for US patients
participating in the PE substudy
Variable PE substudy (n  236)
Sex
Male 160 (67.8%)
Female 76 (32.2%)
Age, n (%)
65 y 63 (26.7%)
65-74 y 86 (36.6%)
75-84 y 77 (32.6%)
85 y 10 (4.2%)
Mean age (y) 69.98
SD (y) 10.40
Range (y) 28-96
Race
White 208 (88.1%)
Black 22 (9.3%)
Asian 0 (0.00%)
Other 6 (2.5%)
PE, Pharmacoeconomic.analysis.
nstruc
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average cost of a hospital day on a general ward was
estimated to be $700 according to a national cost-of-living
index reflecting a national average of 314 cities ($645 in
2002 adjusted to 2004 dollars).9 The cost of an ICU day was
assumed to be $2500 on the basis of current literature and
national hospital statistics.10,11 By using these cost data and
the incremental total and ICU lengths of stay associated
with PMII events in our study, we estimated the cost
associated with PMII events.
Descriptive statistics were performed to compare and
contrast significant differences in resource utilization by the
presence of PMII events through day 30 after surgery.
Descriptive statistics including the mean, median, standard
deviation, and range collectively provided an interpretation
of the distributional characteristics of the data. The degree
and type of missing data were explored and documented.
Frequencies of missing data were assessed overall and strat-
ified by treatment group, and 2 tests were used to determine
whether the rate of the missing data varied widely across the
treatment groups at either baseline or day 30. Analysis of
variance P values and 2 tests of association were reported for
resource use; however, the nonparametric Wilcoxon test was
also performed for certain continuous variables in resource
use, such as length of stay and ICU stay. Nonparametric tests
such as the Wilcoxon test were used if the assumption of
normality was untenable. For categorical variables, the analy-
ses were conducted via 2 tests of association. Statistical sig-
nificance was inferred for P .05.
RESULTS
Of the 370 patients enrolled in US sites for the trial,
Table III. All-cause mortality and PMII-related events ov
Event Overall AAA Afem
Death 8 (3.4%) 2 (4.6%) 1 (3.5%
PMII death 7 (3.0%) 1 (2.3%) 1 (3.5%
PMII overall 42 (17.8%) 9 (20.5%) 7 (24.1
MI (nonfatal) 22 (9.3%) 5 (11.4%) 4 (13.8
CHF 11 (4.7%) 2 (4.6%) 3 (10.3
ARH 12 (5.1%) 3 (6.8%) 2 (6.9%
MI, CHF, arrhythmia, and death were not mutually exclusive. There were
AAA, Abdominal aortic aneurysm repair; Afem, aortoiliofemoral reconstru
Femtib, reconstructions for femorotibial disease; ExtrA, extra-anatomic reco
MI, myocardial infarction; CHF, new or worsened congestive heart failure;
Table IV. Index hospitalization length of stay data throug
Resource utilization item
No. patients still hospitalized from index operation at day 30
Mean length of index stay, d (SD)
No. patients requiring ICU stay during index hospitalization
Mean ICU length of stay during index hospitalization, d (SD)
PMII, Perioperative myocardial ischemic injury; PE, pharmacoeconomic; IC236 (69%) also participated in the PE substudy. The distri-bution of index procedures performed in these patients is
shown in Table I. The patient demographics for the sub-
study are shown in Table II. Differences in the distribution
of race, age, and index procedures were similar (no signif-
icant differences) across treatment groups in both the entire
clinical trial and the sample used for the substudy.
Table III summarizes the procedure-specific and over-
all perioperative (30-day) clinical event rates for the PE
substudy. The 30-day all-cause mortality rate was 8 (3.4%)
of 236, and 7 of 8 deaths (3.0% of the study cohort) were
related to PMII. The 30-day rate of clinical PMII events
(fatal and nonfatal) was 17.8% (42 patients experienced 45
events). There were no significant differences in the pro-
portions of patients who experienced clinical events be-
tween the overall clinical study and the PE substudy group.
There were no significant differences in the incidence of
PMII events when placebo-treated patients were compared
with patients treated with each of the zoniporide dosing
regimens.8 In the patients receiving zoniporide, the inci-
dence of PMII events was 16.3%, compared with 15.7% in
the placebo group (P  .5). In addition, there were no
significant differences in the mortality and PMII morbidity
rates among the different index procedures (Table III). For
this reason, the resource utilization data from the placebo
and treatment groups and from the various index proce-
dures have been pooled.
The effect of PMII events was seen primarily during the
hospitalization for the index vascular procedure (Table IV).
The experience of a PMII event was a significant predictor
of increased resource utilization as measured by hospital
length of stay and ICU stay. Patients who experienced a
PMII event stayed approximately 7 days longer in the
and by index procedure
Fempop Femtib ExtrA Misc
2 (3.2%) 2 (2.8%) 1 (4.4%) 0
2 (3.2%) 2 (2.8%) 1 (4.0%) 0
8 (12.9%) 14 (19.7%) 4 (17.4%) 0
4 (6.5%) 7 (9.9%) 2 (8.7%) 0
1 (1.6%) 4 (5.6%) 1 (4.4%) 0
3 (4.8%) 3 (4.2%) 1 (4.4%) 0
atients who experienced two PMII events.
for occlusive disease; Fempop, reconstructions for femoropopliteal disease;
tions for aortoiliac disease; PMII, perioperative myocardial ischemic injury;
, new cardiac arrhythmia; Misc, miscellaneous.
y 30 by the presence of a PMII event
rall PE substudy
(n  236)
PMII event
P
value
Yes
(n  42)
No
(n  194)
9 (3.8%) 6 (14.3%) 3 (1.6%) .001
11.2 (7.4) 16.8 (8.9) 10.0 (6.4) .001
156 (66.1%) 35 (83.3%) 121 (62.4%) .009
4.4 (4.6) 6.6 (6.3) 3.7 (3.7) .009
tensive care unit.erall
)
)
%)
%)
%)
)
three p
ctionsh da
Ovehospital and approximately 3 days longer in the ICU than
R, em
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PMII event were four times more likely to still be hospital-
ized at day 30.
Hospital follow-up data are shown in Table V. Patients
who had a PMII event were twice as likely to require an
emergency room visit after discharge from the index pro-
cedure and were more than four times as likely to require
ICU care if rehospitalized.
Table VI describes the key incremental costs associated
with PMII events. The incremental cost of a PMII event in
this PE substudy is conservatively estimated at $9980 per
event. Given the fatal and nonfatal PMII event rate of
17.8% in this trial, the total cost of PMII in this study was
estimated at approximately $419,000. Using the incremen-
tal cost and event rates from the trial, the cost of PMII
Table V. ER visits and rehospitalization through day 30 b
Resource utilization item
Ove
No. patients requiring an ER visit after discharge from
index hospital stay
Mean number of ER visits 0
No. patients requiring rehospitalization for any reason
Length of revisit, d (SD)
No. patients requiring ICU stay during
rehospitalization for any reason
ICU stay, d (SD)
Number (%) of patients requiring rehospitalization for
vascular problems
Length of revisit, d (SD)
No. patients requiring rehospitalization for cardiac
problems
Length of revisit, d (SD)
PMII, Perioperative myocardial ischemic injury; PE, pharmacoeconomic; E
Table VI. Incremental cost of a PMII event during the
index hospital stay
Resource use No. days
Unit cost per day
(2004 USD) Total cost
Subjects without a
PMII event
Index hospital
days (total) 10 — $13,660
Ward days 6.3 $700 $4410
ICU days 3.7 $2500 $9250
Subjects with a
PMII event
Index hospital
days (total) 16.8 — $23,640
Ward days 10.2 $700 $7140
ICU days 6.6 $2500 $16,500
Incremental cost
of a PMII
event $9980
PMII, Perioperative myocardial ischemic injury; USD, US dollars; ICU,
intensive care unit.events projected on a national basis is $444 million annu-ally, assuming that half (250,000) of the more than
500,000 patients undergoing open surgical procedures
meet high-risk criteria.
A significant number of missing data were noted for
data collected on discharge status, activities of daily living,
and work loss. For the one third of the PE substudy
population that answered these questions, approximately
34% were discharged to a skilled nursing facility, 22% to an
acute rehabilitation center, 20% to a subacute or postacute
rehabilitation center, 3% to an intermediate care facility,
12% to home with assistance (half paid/half unpaid care),
and 1.5% to home without assistance. For assistance with
activities of daily living after hospital discharge, 73% re-
quired assistance with housekeeping, 33% with leisure ac-
tivities, 78% with preparingmeals, 81% with transportation,
and 54%with self-care. Thework-loss questionswere typically
not answered; only 14 patients reported being unable to do
their paid or volunteer work after hospital discharge. Because
of the missing data and concern as to whether the data
would be representative of the entire PE substudy, the
effect of PMII events on these areas was not assessed.
DISCUSSION
This study is the only large multicenter prospective trial
measuring the incidence of and resource utilization associ-
ated with cardiac complications of noncardiac vascular sur-
gery. One older economic burden projection estimated
that perioperative MI alone cost more than $500 million
annually for patients undergoing all noncardiac operations
(approximately $25 million annually in the United States).1
Prospective systematic assessments of the burden of PMII
events after noncardiac vascular surgery have not been
reported previously.
Our cost results are in line with a recent publication by
Fleisher et al,12 who conducted a retrospective analysis of
Medicare data in patients who underwent abdominal aortic
presence of a PMII event
E substudy
236)
PMII event
P
value
Yes
(n  42)
No
(n  194)
12.7%) 10 (23.8%) 20 (10.3%) .02
0.33) 0.24 (0.43) 0.10 (0.30) NS
11.9%) 6 (14.3%) 22 (11.3%) NS
4.7) 4.3 (2.9) 7.4 (4.8) NS
2.5%) 3 (7.1%) 3 (1.6%) .04
0.3) 3 (1.7) 1.7 (1.2) NS
5.1%) 0 (0%) 12 (6.2%) .10
5.2) — 9.1 (5.2) —
1.3%) 1 (2.4%) 2 (1.0%) .48
1.2) 5 4 (1.4) .67
ergency room; ICU, intensive care unit; NS, not significant.y the
rall P
(n 
30 (
.13 (
28 (
6.9 (
6 (
2.3 (
12 (
9.1 (
3 (
4.3 (aneurysm repair. The incremental charges associated with a
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costs assuming a 0.75 cost-to-charge ratio). The incremental
charges associated with a perioperative death were $21,909
(approximately $16,432 in costs). In our study, the incremen-
tal cost of a PMII event was estimated at almost $10,000 for a
mix of aortic and more distal noncardiac vascular procedures.
Not surprisingly, the key cost drivers identified in this study
were hospital and ICU lengths of stay.
We conservatively estimate that the current cost of
PMII events for the highest-risk patients undergoing non-
cardiac vascular procedures is more than $440 million
annually in the United States. The implications of the
burden of illness of PMII events for physicians, hospital
decision-makers, and national policy-makers are substan-
tial. Over the coming decades, the elderly population is
expected to grow by 25% to 35%.5 Projections suggest that
the overall number of noncardiac surgical procedures will
double in this age group (currently 6-8 million) to nearly
12 million annually.5 It is in this elderly age group that
there is the highest risk of PMII morbidity/mortality after
surgery. Even if we assume PMII event rates as low as 5%,
this would result in a staggering burden when considering
the projected growth of vascular and general surgical pro-
cedures in the coming years.
Aggressive preoperative surgical and interventional
management of coronary disease has been touted as a
potentially effective means for managing perioperative car-
diac risk.7 The recent Coronary Artery Revascularization
Prophylaxis trial, however, showed that preoperative surgi-
cal or catheter-based coronary revascularization was inef-
fective in preventing perioperative MI and in decreasing
longer-term mortality in selected patients scheduled for non-
cardiac vascular surgery.13 The rate of perioperative MI was
12% in the revascularization group and 14% in the nonrevas-
cularization group (P  .37), and the mortality at a mean
follow-up of 2.7 years was 22% in the no-revascularization
group and 23% in the revascularization group ( P   .92).13
Although the highest-risk cardiac patients (left main steno-
sis 50%, ejection fraction 20%, and severe aortic steno-
sis) were excluded from the trial, the results do suggest that
prophylactic coronary revascularization in most vascular
surgery patients is unlikely to be effective in preventing
PMII or its related mortality.13
On a more hopeful and positive note, -blockers have
been shown to be effective in the prevention of periopera-
tive MI and cardiac-related mortality in patients undergo-
ing open aneurysm repair.14 In their very important study,
Poldermans et al14 selected a group of high-risk patients
undergoing vascular surgery for randomization to standard
perioperative care vs standard perioperative care plus biso-
prolol. Perioperative cardiac death was 3.4% in the bisopro-
lol group and 17% in the control group (P .02). Nonfatal
MI occurred in none of the bisoprolol group and in 17% of
the control group (P  .001).14 Bisoprolol was, therefore,
highly effective in preventing PMII in this study.
In a much larger survey of high-risk patients undergo-
ing noncardiac surgery in the United States, Lindenauer et
al15 showed that perioperative -blocker therapy was asso-ciated with reduced in-hospital mortality and that the pro-
tective effect of -blockers increased with increasing cardiac
risk. The dramatic effect of -blockade in preventing PMII
in these studies has spawned significant interest in other po-
tential chemoprophylactic regimens using other -blockers,
antiplatelet agents, reductase inhibitors, and newer agents. In
fact, the clinical trial fromwhich our PE data were derivedwas
a study of a new sodium hydrogen ion exchange inhibitor
designed as a potential chemoprophylactic agent.8 Given the
failure of invasive measures to alter perioperative or long-
term cardiac-related mortality in the Coronary Artery Re-
vascularization Prophylaxis trial, large-scale chemoprophy-
lactic trials must be performed to determine the optimal
means for preventing PMII.
This study has several limitations, including the short
30-day follow-up, which likely resulted in an underestima-
tion of the true economic burden of PMII events. Further-
more, missing data in the assessment of quality of life after
discharge made analysis of the effect of PMII on posthos-
pitalization quality of life, non–hospitalization-related eco-
nomic burdens, and noneconomic burdens impossible. An-
other limitation is our lack of detailed data on perioperative
medical therapy in the study cohort, which prevented an
analysis of the effect of -blockers and other medications
on the incidence and resource intensity of PMII events.
However, our substudy was designed to establish the inci-
dence of and resource utilization associated with PMII in
current vascular practice and not to assess the benefit of any
particular regimen. The limited sample of patients who
experienced PMII events (42 of 236 patients) prevented
meaningful subanalyses of PMII for specific surgical proce-
dures. Thus, we were unable to determine whether the
overall findings of increased resource utilization after a
PMII event hold equally true for each of the individual
surgical procedures included in the trial. Increasing the
sample size by analyzing the global data might have pro-
vided sufficient statistical power, although it would be
difficult to apply global findings to specific countries or
health care systems. In addition, our method of estimating
cost by using resource utilization as reflected in length of
stay and ICU utilization probably underestimates cost.
Geographic and interinstitutional variations in charges and
in cost-charge ratios made the use of individual hospital
bills problematic and equally subject to error.
Our study differs from other studies of perioperative
cardiac morbidity and mortality in our definition of cardiac
morbidity andmortality. Inmany studies, fatal and nonfatal
MI is the only end point. In this study we used a broader
definition of PMII that included CHF and new significant
arrhythmias along with infarction. By including these end
points, which, although less precisely quantifiable, were
adjudicated by an end point committee, we hoped to
capture all PMII events likely to influence resource utiliza-
tion and thereby achieve a more accurate assessment of
PMII effects.
In conclusion, in current vascular practice, PMII re-
mains common, affecting 17.8% of subjects in this prospec-
tive clinical trial. The occurrence of a PMII event in this
JOURNAL OF VASCULAR SURGERY
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length of stay, ICU utilization, postdischarge emergency
ward visits, and cost. Strategies to decrease the incidence of
PMII, such as chemoprophylactic regimens and the use of
less invasive endovascular vascular interventions in high-
risk patients, should be evaluated in large-scale prospective
trials to determine the optimal means for preventing PMII
and to determine their effect on costs and outcomes.
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